Pediatric Brain Tumor Clinical Trials

Questions about patients' participation in the following clinical trials can be directed to the study coordinator at (415) 353-9387 or a nurse practitioner at (415) 514-0238.

Newly Diagnosed Tumor

Diffuse Intrinsic Brainstem Glioma (DIPG)

Phase 2 Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (Dana Farber Cancer Institute Study DFCI-DIPG).

Ependymoma

Phase 3 Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma, Ages 1 to 21 years (Childrens Oncology Group Study ACNS0831). Study Details

Medulloblastoma and Primitive Neural Ectodermal Tumor (PNET)

Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients (Children’s Oncology Group Study ACNS0332)

A Phase 2 Study for the Treatment of Non-metastatic Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age (Children’s Oncology Group Study ACNS1221)

CNS Germ Cell Tumors

Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) (Children’s Oncology Group Study ACNS1123)

Recurrent Disease

Phase 2 Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 001).

Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children with Recurrent/Refractory BRAFV600E-mutant gliomas (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 002). A Phase 2 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low-grade Glioma (Pediatric Brain Tumor Consortium Study 029).

A Phase 2 Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas (Children’s Oncology Group Trial ACNS1022).

A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors (Children’s Oncology Group Trial ADVL1416)

Trials Studying Late Effects of Treatment

Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer (Children's Oncology Group Trial ALTE07C1). Study Details